Dicerna Pharmaceuticals Inc Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018	FY2017 12 months to Dec 31, 2017	FY2016 12 months to Dec 31, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Non-cash litigation expense
Stock-based compensation expense
Change in fair value of derivative liability
Depreciation and amortization expense
Amortization of premium on investments
Lease expense
Other
Changes in operating assets and liabilities:
Litigation settlement payable
Deferred revenue
Prepaid expenses and other assets
Accounts payable
Contract receivables
Withholding tax receivable
Accrued expenses and other liabilities
Lease liability
Other
Deferred charges and other assets
Net cash provided by (used in) operating activities
CASH FLOWS FROM INVESTING ACTIVITIES:
Change in restricted cash equivalents
Maturities of held-to-maturity investments
Purchases of held-to-maturity investments
Purchases of property and equipment
Other
Net cash (used in) provided by investing activities

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of redeemable convertible preferred stock
Redeemable convertible preferred stock issuance costs
Payments of common stock offering costs
Proceeds from exercises of common stock warrants, stock options, and issuances under Employee Stock Purchase Plan
Settlement of restricted stock for tax withholding
Net cash provided by financing activities

INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS
Cash and cash equivalents
Other
Net cash provided by financing activities
NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH EQUIVALENTS
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH EQUIVALENTS – Beginning of year
CASH, CASH EQUIVALENTS AND RESTRICTED CASH EQUIVALENTS – End of year
SUPPLEMENTAL CASH FLOW INFORMATION:
NONCASH OPERATING ACTIVITIES:
Right-of-use assets acquired through operating leases
NONCASH INVESTING ACTIVITIES:
Property and equipment purchases included in accounts payable and accrued expenses
NONCASH FINANCING ACTIVITIES:
Right-of-use assets acquired through finance leases
Conversion of redeemable convertible preferred stock into common stock
Dividends on redeemable convertible preferred stock
Deemed dividend related to beneficial conversion feature of redeemable convertible preferred stock
Deemed dividend on conversion of redeemable convertible preferred stock
Common stock offering costs included in accounts payable or accrued expenses
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
Cash and cash equivalents
Restricted cash equivalents, current
Restricted cash equivalents, noncurrent

Comments